42 related articles for article (PubMed ID: 36592505)
1. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
3. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H;
J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
Friedl TWP; Fehm T; Müller V; Lichtenegger W; Blohmer J; Lorenz R; Forstbauer H; Fink V; Bekes I; Huober J; Jückstock J; Schneeweiss A; Tesch H; Mahner S; Brucker SY; Heinrich G; Häberle L; Fasching PA; Beckmann MW; Coleman RE; Janni W; Rack B
JAMA Oncol; 2021 Aug; 7(8):1149-1157. PubMed ID: 34165508
[TBL] [Abstract][Full Text] [Related]
5. Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study.
Brown J; Paggiosi MA; Rathbone E; Gregory W; Bertelli G; Din O; McCloskey E; Dodwell D; Cameron D; Eastell R; Coleman R
J Bone Miner Res; 2024 Mar; 39(1):8-16. PubMed ID: 38630878
[TBL] [Abstract][Full Text] [Related]
6. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
Beltran-Bless AA; Clemons MJ; Fesl C; Greil R; Pond GR; Balic M; Vandermeer L; Bjelic-Radisic V; Singer CF; Steger GG; Helfgott R; Egle D; Sölkner L; Gampenrieder SP; Kacerovsky-Strobl S; Suppan C; Ritter M; Rinnerthaler G; Pfeiler G; Fohler H; Hlauschek D; Hilton J; Gnant M
Eur J Cancer; 2023 Feb; 180():108-116. PubMed ID: 36592505
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
8. The use of adjuvant bisphophonates in the treatment of early-stage breast cancer.
Mathew A; Brufsky AM
Clin Adv Hematol Oncol; 2014 Nov; 12(11):749-56. PubMed ID: 25674714
[TBL] [Abstract][Full Text] [Related]
9. Clinical research update: zoledronate.
Body JJ
Cancer; 1997 Oct; 80(8 Suppl):1699-701. PubMed ID: 9362440
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
11. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
